May Marks Third Annual Inherited Retinal Disease and Genetic Testing Month: Resources to Protect Vision

Inherited retinal diseases (IRDs) affect thousands of individuals worldwide, often leading to severe vision loss or blindness. To raise awareness and provide critical resources, Prevent Blindness, the nation’s leading patient advocacy organization for eye health, has designated May as the third annual Inherited Retinal Disease and Genetic Testing Month. This initiative aims to educate patients, caregivers, and healthcare professionals about IRDs, the importance of genetic testing, and emerging treatments that could preserve sight.

Understanding Inherited Retinal Diseases (IRDs)

IRDs are a group of genetic disorders that affect the retina, the light-sensitive layer of tissue at the back of the eye. The retina converts light into electrical signals, which are sent to the brain via the optic nerve to create vision. When genetic mutations disrupt this process, it can lead to progressive vision loss or blindness. IRDs can manifest at any age, from infancy to adulthood, and often run in families.

Common types of IRDs include:

• Retinitis Pigmentosa (RP): A leading cause of inherited blindness, RP primarily affects peripheral and night vision, often progressing to central vision loss.
• Stargardt Disease: The most common form of inherited macular degeneration, typically diagnosed in childhood or adolescence, leading to central vision loss.
• Leber Congenital Amaurosis (LCA): A severe form of IRD that appears in infancy, causing profound vision impairment.
• Choroideremia: A rare, X-linked disorder primarily affecting males, leading to progressive night blindness and peripheral vision loss.
• Cone-Rod Dystrophy: A condition where cone cells (responsible for color and central vision) deteriorate before rod cells (responsible for peripheral and night vision).
• Achromatopsia: A rare disorder causing complete or partial color blindness, light sensitivity, and reduced visual acuity.

The Critical Role of Genetic Testing

Genetic testing is a cornerstone in the diagnosis and management of IRDs. By identifying the specific gene mutation responsible for an individual’s condition, healthcare providers can:

• Confirm a diagnosis: Genetic testing can distinguish between similar retinal diseases, ensuring accurate treatment plans.
• Predict disease progression: Some gene mutations are associated with faster or slower rates of vision loss, helping patients and doctors prepare for future needs.
• Identify eligibility for clinical trials: Many emerging therapies target specific gene mutations. Genetic testing can connect patients with trials for treatments like gene therapy, stem cell therapy, or pharmacological interventions.
• Inform family planning: IRDs are often hereditary. Genetic testing can support families understand their risk of passing the condition to future generations.

Even as genetic testing is available for most IRDs, it is not yet universally accessible. Barriers include cost, limited awareness among patients and providers, and the complexity of interpreting results. Prevent Blindness and other advocacy groups are working to address these challenges by expanding access to testing and education.

Resources Available During IRD and Genetic Testing Month

Prevent Blindness has curated a comprehensive suite of free resources to support patients, caregivers, and healthcare professionals during May’s awareness campaign. These include:

Educational Materials

• Webpages: Dedicated sections on IRDs and Stargardt disease, featuring up-to-date information on symptoms, diagnosis, and management.
• Fact Sheets: Downloadable guides in English and Spanish covering IRDs, genetic testing, and specific conditions like retinitis pigmentosa and Stargardt disease.
• Social Media Graphics: Shareable content to help spread awareness on platforms like Facebook, Instagram, and Twitter.

Multimedia Content

• Focus on Eye Health Series: A new episode, “Stargardt Disease: A Conversation with Bryan and Bradford Manning of Two Blind Brothers,” features the Manning brothers discussing their journey with Stargardt disease, offering advice for parents of children with the condition, and sharing their perform with their nonprofit, Two Blind Brothers, which funds research to cure blindness.
• Expert Videos: Interviews with medical professionals, including Dr. Elias Traboulsi, a pediatric ophthalmologist and geneticist at the Cleveland Clinic, and Dr. Alina V. Dumitrescu, a clinical associate professor of ophthalmology at the University of Iowa Hospitals and Clinics, discussing IRDs and genetic testing.
• Podcast Episode: The Focus on Eye Health Podcast features the Manning brothers’ conversation, providing insights into living with Stargardt disease and advocating for research.

Stargardt Disease Week

Prevent Blindness has designated the third week of May as Stargardt Disease Week, offering targeted resources for individuals with Stargardt disease and their care partners. These include:

• A dedicated webpage with information on symptoms, diagnosis, and management.
• Social media graphics and fact sheets in English and Spanish.
• Videos featuring personal stories and expert advice.

Promising Advances in IRD Treatment

While there is currently no cure for most IRDs, research is advancing rapidly, offering hope for future treatments. Some of the most promising developments include:

Gene Therapy

Gene therapy aims to correct or replace faulty genes responsible for IRDs. One notable success is Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for a rare form of LCA caused by mutations in the RPE65 gene. Luxturna restores vision in some patients by delivering a functional copy of the gene directly to retinal cells.

Stem Cell Therapy

Stem cell research is exploring ways to replace damaged retinal cells with healthy ones. Early-stage clinical trials are underway to evaluate the safety and efficacy of stem cell therapies for conditions like retinitis pigmentosa and Stargardt disease.

Pharmacological Treatments

Several drugs are in development to slow or halt the progression of IRDs. For example, emixustat, an oral medication, is being studied for its potential to slow vision loss in Stargardt disease by reducing the accumulation of toxic byproducts in the retina.

Retinal Prosthetics

Devices like the Argus II Retinal Prosthesis System can restore partial vision in individuals with advanced retinitis pigmentosa. These implants bypass damaged retinal cells and stimulate the remaining healthy cells to create visual perceptions.

How to Get Involved

Raising awareness about IRDs and genetic testing is critical to improving outcomes for patients. Here’s how you can participate in Inherited Retinal Disease and Genetic Testing Month:

• Educate Yourself: Visit Prevent Blindness’s IRD webpage to learn more about these conditions and genetic testing.
• Share Resources: Use the provided social media graphics and fact sheets to spread awareness among your network.
• Advocate for Access: Support policies that expand access to genetic testing and emerging treatments for IRDs.
• Participate in Research: If you or a loved one has an IRD, consider enrolling in a clinical trial. Visit ClinicalTrials.gov to uncover studies near you.
• Donate: Contribute to organizations like Prevent Blindness or Foundation Fighting Blindness to support research and patient advocacy.

Key Takeaways

• Inherited retinal diseases (IRDs) are genetic disorders that cause progressive vision loss or blindness by affecting the retina’s ability to process light.
• May is the third annual Inherited Retinal Disease and Genetic Testing Month, led by Prevent Blindness to raise awareness and provide free educational resources.
• Genetic testing is essential for accurate diagnosis, predicting disease progression, and connecting patients with clinical trials for emerging treatments.
• Resources available during May include webpages, fact sheets, videos, and a podcast episode featuring experts and individuals living with IRDs.
• Stargardt Disease Week (the third week of May) offers targeted support for individuals with Stargardt disease and their care partners.
• Promising research in gene therapy, stem cell therapy, pharmacological treatments, and retinal prosthetics is offering new hope for preserving and restoring vision.

FAQs About Inherited Retinal Diseases

What are the early signs of an inherited retinal disease?

Early signs of IRDs vary by condition but may include:

• Night blindness or difficulty seeing in low light (common in retinitis pigmentosa).
• Loss of central vision, making it hard to read or recognize faces (common in Stargardt disease).
• Light sensitivity or glare (common in achromatopsia).
• Color vision abnormalities.
• Blurred or distorted vision.

If you or a loved one experiences these symptoms, consult an eye care professional for a comprehensive evaluation.

How are IRDs diagnosed?

Diagnosing an IRD typically involves:

• A comprehensive eye exam, including visual acuity and visual field tests.
• Retinal imaging, such as optical coherence tomography (OCT) or fundus autofluorescence, to assess retinal structure and function.
• Electroretinography (ERG), which measures the electrical responses of retinal cells to light.
• Genetic testing to identify the specific gene mutation responsible for the condition.

Is there a cure for IRDs?

Currently, there is no cure for most IRDs. However, research is advancing rapidly, and several treatments are in development or have received FDA approval for specific conditions. Gene therapy, stem cell therapy, and pharmacological treatments show promise in slowing or halting disease progression and, in some cases, restoring vision.

How can genetic testing help if there’s no cure?

Even without a cure, genetic testing provides several benefits:

• Accurate Diagnosis: Genetic testing can confirm or refine a diagnosis, helping patients and doctors understand the specific condition and its likely progression.
• Clinical Trial Eligibility: Many emerging treatments target specific gene mutations. Genetic testing can identify patients who may benefit from these therapies.
• Family Planning: IRDs are often hereditary. Genetic testing can help families understand their risk of passing the condition to future generations.
• Personalized Management: Knowing the genetic cause of an IRD can help doctors tailor management strategies, such as recommending specific low-vision aids or lifestyle adjustments.

What should I do if I suspect I have an IRD?

If you suspect you or a loved one has an IRD, take the following steps:

1. Schedule an Eye Exam: Visit an ophthalmologist or a retinal specialist for a comprehensive evaluation. Be sure to mention any family history of vision loss or blindness.
2. Request Genetic Testing: Ask your doctor about genetic testing to identify the specific gene mutation causing your symptoms. This can help guide your treatment and management plan.
3. Seek Support: Connect with organizations like Prevent Blindness or Foundation Fighting Blindness for resources, education, and community support.
4. Explore Clinical Trials: Visit ClinicalTrials.gov to learn about ongoing research and potential opportunities to participate in studies.

A Look Ahead: The Future of IRD Treatment

The landscape of IRD treatment is evolving rapidly, with research offering new hope for patients and families. As gene therapy, stem cell therapy, and pharmacological treatments continue to advance, the possibility of preserving or even restoring vision for individuals with IRDs is becoming increasingly realistic. Initiatives like Inherited Retinal Disease and Genetic Testing Month play a vital role in raising awareness, expanding access to testing, and accelerating research.

For those living with an IRD, staying informed and connected to the latest developments is key. By leveraging resources from organizations like Prevent Blindness, advocating for access to care, and participating in research, patients and their families can take an active role in shaping a future where IRDs no longer lead to irreversible vision loss.

To learn more about IRDs and genetic testing, visit Prevent Blindness’s IRD webpage and explore the free resources available during May’s awareness campaign.